

Financial news for CLSN dated on 2020-05-29: Celsion Reports Data On Phase II Ovarian Cancer Study

Financial news for CLSN dated on 2020-05-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for CLSN dated on 2020-05-26: 71 Biggest Movers From Friday

Financial news for CLSN dated on 2020-05-22: 46 Stocks Moving In Friday's Mid-Day Session

Financial news for CLSN dated on 2020-05-22: Stocks That Hit 52-Week Highs On Friday

Financial news for CLSN dated on 2020-05-22: Mid-Morning Market Update: Markets Fall; Alibaba Earnings Beat Estimates

Financial news for CLSN dated on 2020-05-22: 30 Stocks Moving in Friday's Pre-Market Session

Financial news for CLSN dated on 2020-05-15: Celsion shares are trading lower after the company reported worse-than-expected Q1 EPS results.

Financial news for CLSN dated on 2020-05-15: Celsion Q1 EPS \$(0.200) Misses \$(0.170) Estimate

Financial news for CLSN dated on 2020-05-15: Earnings Scheduled For May 15, 2020

Financial news for CLSN dated on 2020-04-23: Celsion Wins \$2.5M In Non-Dilutive Funding From Sale Of New Jersey State Net Operating Losses, Grant Funding Under Paycheck Protection Program

Financial news for CLSN dated on 2020-04-15: UPDATE: Celsion Says Independent Data Monitoring Committee Expected To Meet In Jul. 2020 To Conduct Second Interim Analysis

Financial news for CLSN dated on 2020-04-15: Celsion Reports Prescribed Minimum Number Of Events Of 158 Patient Deaths Has Been Reached For Second Pre-Specified Interim Analysis Of OPTIMA Phase 3 Study Of ThermoDox

Financial news for CLSN dated on 2020-03-26: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger

Financial news for CLSN dated on 2020-03-26: Celsion's OVATION 1 Study With GEN-1 In Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm

Financial news for CLSN dated on 2020-03-25: Celsion Q4 EPS \$(0.77) Down From \$(0.68) YoY, Sales \$500K, Same YoY

Financial news for CLSN dated on 2020-03-23: Celsion's GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency

Financial news for CLSN dated on 2020-03-19: Celsion Announces Initial Clinical Results From Phase I Portion Of Phase I/II OVATION 2 Study With GEN-1 In Patients With Advanced Ovarian Cancer

Financial news for CLSN dated on 2020-03-03: Celsion Chair, Pres, CEO Sends Letter To Shareholders

Financial news for CLSN dated on 2020-02-28: Stocks That Hit 52-Week Lows On Friday

Financial news for CLSN dated on 2020-02-04: Celsion Highlights Presentation Of ThermoDox Trial Data By Medical Professor At SPECTRUM 2020 Interventional Oncology Conference

Financial news for CLSN dated on 2020-01-22: 98 Biotechnology Stocks Moving In Wednesday's Session

Financial news for CLSN dated on 2020-01-22: 116 Healthcare Stocks Moving In Wednesday's Session

Financial news for CLSN dated on 2019-12-29: Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

Financial news for CLSN dated on 2019-12-18: Celsion Shares Tick Slightly Higher As Hearing Co. Granted European Patent Number EP2814464 For 'Thermosensitive nanoparticle formulations and method of making the same'

Financial news for CLSN dated on 2019-11-15: Earnings Scheduled For November 15, 2019

Financial news for CLSN dated on 2019-11-14: Celsion Q3 EPS \$(0.25) Beats \$(0.28) Estimate, Sales \$125K Beat \$80K Estimate

Financial news for CLSN dated on 2019-11-14: Celsion Offers Comment On Common Stock Purchase Deal With Aspire Capital

Financial news for CLSN dated on 2019-11-14: Celsion Highlights Publication Of Research On Fluorescence Imaging Of ThermoDox Uptake In Int'l. Journal Of Hyperthermia

Financial news for CLSN dated on 2019-11-13: Stocks That Hit 52-Week Lows On Wednesday

Financial news for CLSN dated on 2019-11-04: Stocks That Hit 52-Week Lows On Monday

Financial news for CLSN dated on 2019-11-04: Celsion Reports Independent Data Monitoring Committee Unanimously Voted For Recommendation To Continue Phase 3 OPTIMA Study Of ThermoDox In Primary Liver Cancer

Financial news for CLSN dated on 2019-08-14: Celsion Q2 EPS \$(0.29) Beats \$(0.32) Estimate, Sales \$125K Miss \$130K Estimate

Financial news for CLSN dated on 2019-08-13: Celsion Highlights Publication Of Results Of NIH Analysis Of ThermoDox In Journal Of Vascular And Interventional Radiology

Financial news for CLSN dated on 2019-08-09: Celsion Highlights GEN-1 Immunotherapy In Oppenheimer's Expert Call On Ovarian Cancer Treatment Landscape, Emerging Opportunities

Financial news for CLSN dated on 2019-07-26: 30 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for CLSN dated on 2019-06-20: Celsion shares are trading higher after the company announced it received IRB approval to begin the clinical study of ThermoDox in combination with MR-HIFU.

Financial news for CLSN dated on 2019-06-20: Celsion Receives IRB Approval To Begin A Clinical Study Of ThermoDox Plus High Intensity Focused Ultrasound In Breast Cancer Patients At University Medical Center Utrecht In Netherlands

Financial news for CLSN dated on 2019-05-15: Celsion Q1 EPS \$(0.12) Beats \$(0.27) Estimate, Sales \$125K Miss \$130K Estimate

Financial news for CLSN dated on 2019-04-17: Celsion Corporation Announces Issuance Of New Patent For ThermoDox

Financial news for CLSN dated on 2019-04-04: 55 Biggest Movers From Yesterday

Financial news for CLSN dated on 2019-03-29: Celsion Q4 EPS \$(0.27) Misses \$(0.14) Estimate, Sales \$125K Miss \$130K Estimate

Financial news for CLSN dated on 2019-03-29: Earnings Scheduled For March 29, 2019

Financial news for CLSN dated on 2019-03-04: Celsion Highlights Presentation Of GEN-1 Data At ASCO-SITC Clinical Immuno-Oncology Symposium

Financial news for CLSN dated on 2019-01-24: 54 Biggest Movers From Yesterday

Financial news for CLSN dated on 2019-01-17: Celsion Announces Publication Of ThermoDox Study Results In Radiology Journal

Financial news for CLSN dated on 2019-01-15: Celsion To Present GEN-1 Data At Upcoming ASCO-SITC Clinical Immuno-Oncology Symposium On Mar. 2, 2019

Financial news for CLSN dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for CLSN dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for CLSN dated on 2018-12-19: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Financial news for CLSN dated on 2018-12-18: Celsion Reports Independent Data Monitoring Committee For Co.'s Pivotal Phase III OPTIMA Study Of ThermoDox In Combo With RFA For Living Cancer Unanimously Recommended Study Continue

Financial news for CLSN dated on 2018-12-06: Celsion Says May Offer And Sell Shares

Of Co's Common Stock Having An Aggregate Offering Price Of Up To \$16 Mln From Time To Time

Financial news for CLSN dated on 2018-12-03: Celsion Receives \$11.1M Allocation Through New Jersey Technology Business Tax Certificate Transfer (NOL) Program

Financial news for CLSN dated on 2018-11-23: Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018

Financial news for CLSN dated on 2018-11-21: Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018

Financial news for CLSN dated on 2018-11-21: The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelson CEO

Financial news for CLSN dated on 2018-11-14: Celsion Corporation Q3 EPS \$(0.26) Misses \$(0.22) Estimate, Sales \$125K Miss \$130K Estimate

Financial news for CLSN dated on 2018-10-24: Celsion Announces Date From Phase I Immuno-Oncology Study In Ovarian Cancer Patients; Data Showed GEN-1 Was Tolerated And That Intraperitoneal Administration Is Feasible With Broad Patient Acceptance

Financial news for CLSN dated on 2018-09-23: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for CLSN dated on 2018-09-16: The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for CLSN dated on 2018-09-10: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for CLSN dated on 2018-09-09: The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs

Financial news for CLSN dated on 2018-09-07: Celsion S-3 Shows Registration For \$75M Mixed Securities Shelf Offering

Financial news for CLSN dated on 2018-09-06: Celsion Announces First Patient Is Enrolled In OVATION II Study

Financial news for CLSN dated on 2018-09-04: Celsion Announces Approval of Its Application to Sell Net Operating Losses for up to \$10M in Non-Dilutive Funding

Financial news for CLSN dated on 2018-09-04: Celsion Announces Agreement With Aspire Capital Fund For Offering Of \$15M Plus 164,835 Commitment Shares

Financial news for CLSN dated on 2018-08-14: Celsion Says Quarterly and Year-to-Date Cash Expenses Consistent With Prior Guidance

Financial news for CLSN dated on 2018-08-14: Celsion Q2 EPS \$(0.46) Up From \$(0.79) YoY, Sales \$125K Inline

Financial news for CLSN dated on 2018-07-10: Celsion Announces Publication Of Thermodox Phase I Clinical Study Results In The Lancet Oncology Journal

Financial news for CLSN dated on 2018-06-30: The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus

Financial news for CLSN dated on 2018-06-28: Celsion Announces a \$10M Loan From Horizon Technology

Financial news for CLSN dated on 2018-06-20: 48 Biggest Movers From Yesterday

Financial news for CLSN dated on 2018-06-19: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLSN dated on 2018-05-11: Celsion Q1 EPS \$(0.25) Beats \$(0.30) Estimate, Sales \$125K Miss \$130K Estimate

Financial news for CLSN dated on 2018-05-11: Earnings Scheduled For May 11, 2018

Financial news for CLSN dated on 2018-04-09: Celsion CEO Michael Tardugno Buys 2,500 @ Avg Price: \$2.30 -Form4

Financial news for CLSN dated on 2018-03-27: Celsion Reports FY17 EPS \$(2.72) Misses \$(1.13) Est., Sales \$500K Inline With \$500K Estimate

Financial news for CLSN dated on 2018-03-27: Celsion Reports FY17 EPS \$(2.72) vs

\$(11.89) In Prior Year Period, Sales \$500K vs \$500K In Prior Year Period

Financial news for CLSN dated on 2018-03-27: Earnings Scheduled For March 27, 2018

Financial news for CLSN dated on 2018-03-05: Celsion CORP: Tardugno Michael H (Director, Chairman, President and CEO) Buys 7,500 @ Avg Price: \$2.38 (Form4)

Financial news for CLSN dated on 2018-03-05: Celsion Expects To Begin Enrollment Of Phase I Portion Of The OVATION II Study Of GEN-1 During First Half Of 2018 In Up to 90 Patients, Says Phase I/II Study Will Be Powered To Show A 33% Improvement In The Primary Endpoint, Progression Free Survival

Financial news for CLSN dated on 2018-01-18: Celsion Offers Corporate Update, '18 Outlook

Financial news for CLSN dated on 2018-01-04: Celsion Reports FDA Clearance Of OVATION II Study For Evaluation Of GEN-1 Immunotherapy To Treat Newly Diagnosed Stage III/IV Ovarian Cancer

Financial news for CLSN dated on 2017-12-28: 30 Biggest Movers From Yesterday

Financial news for CLSN dated on 2017-11-24: 40 Biggest Movers From Wednesday

Financial news for CLSN dated on 2017-11-22: 35 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLSN dated on 2017-11-22: 32 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLSN dated on 2017-11-22: 40 Biggest Movers From Yesterday

Financial news for CLSN dated on 2017-11-21: Mid-Afternoon Market Update: Dow Gains 180 Points; DSW Shares Drop On Earnings Miss

Financial news for CLSN dated on 2017-11-21: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLSN dated on 2017-11-21: Mid-Day Market Update: Signet Jewelers Falls After Q3 Results; Cheetah Mobile Shares Surge

Financial news for CLSN dated on 2017-11-21: Mid-Morning Market Update: Markets Open Higher; Lowe's Tops Q3 Expectations

Financial news for CLSN dated on 2017-11-21: Oppenheimer Initiates Coverage On Celsion with Outperform Rating, Announces \$9.00 Price Target

Financial news for CLSN dated on 2017-11-21: 33 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLSN dated on 2017-11-20: 7 Stock's Moving In Monday's After-Hours Session

Financial news for CLSN dated on 2017-11-20: STAT's Adam Feurstein Tweets: 'There's an analyst named Hartaj Singh at Oppenheimer who just initiated on \$CLSN and \$SNSS w/ outperform ratings, \$9 and \$7 PTs, respectively. Poor guy. FHL.'

Financial news for CLSN dated on 2017-11-14: 42 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CLSN dated on 2017-11-14: 34 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLSN dated on 2017-11-14: Celsion Reports Q3 EPS \$(0.70) vs \$(0.56) Est., Sales \$125K vs \$60K Est.

Financial news for CLSN dated on 2017-11-13: UPDATE: Celsion Submitted Phase I/II Trial Protocol To FDA For 30-Day Review, Expects To Initiate Enrollment Of Phase I In 1H18, To Be 50% Enrolled By End of 2018

Financial news for CLSN dated on 2017-11-13: Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer

Financial news for CLSN dated on 2017-11-13: 28 Stocks Moving In Monday's Mid-Day Session

Financial news for CLSN dated on 2017-10-30: 50 Biggest Movers From Friday

Financial news for CLSN dated on 2017-10-27: 45 Stocks Moving In Friday's Mid-Day Session

Financial news for CLSN dated on 2017-10-18: Celsion Offers Summary Of R&D Day Held On Oct 12: Discussed 'GEN-1 Clinical Programs in Newly Diagnosed Stage III/IV Ovarian Cancer Patients'

Financial news for CLSN dated on 2017-10-18: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLSN dated on 2017-10-16: 38 Biggest Movers From Friday

Financial news for CLSN dated on 2017-10-13: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for CLSN dated on 2017-10-12: 33 Stocks Moving In Thursday's Mid-Day Session

Financial news for CLSN dated on 2017-10-12: Celsion To Hold R&D Day Today 4pm-6pm ET

Financial news for CLSN dated on 2017-10-12: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for CLSN dated on 2017-10-11: 28 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CLSN dated on 2017-10-11: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLSN dated on 2017-10-10: 12 Biggest Mid-Day Gainers For Tuesday

Financial news for CLSN dated on 2017-10-10: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLSN dated on 2017-10-05: Maxim Group Upgrades Celsion to Buy

Financial news for CLSN dated on 2017-10-05: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for CLSN dated on 2017-10-04: Celsion Corporation Reports Gross Proceeds of \$15.6M from the Exercise of Existing Common Stock Warrants

Financial news for CLSN dated on 2017-10-04: 18 Biggest Mid-Day Losers For Wednesday

Financial news for CLSN dated on 2017-10-04: Celsion Lower In Volatile Session

Financial news for CLSN dated on 2017-10-04: Celsion Shares Spiking Higher As Hearing Maxim Upgraded Co. To Buy

Financial news for CLSN dated on 2017-10-04: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CLSN dated on 2017-10-03: UPDATE: Celsion Highlights 'Clear Evidence of Biological Activity Including Dose Dependent Increases in Inflammatory Cytokines (IL-12, IFN-g), Decreases in VEGF Levels and No Dose Limiting Toxicities'

Financial news for CLSN dated on 2017-10-03: Celsion Reports Final Clinical, Translational Research Data From OVATION Study At AACR: '100% Disease Control; 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated in Four Dose-Escalating Cohorts'

Financial news for CLSN dated on 2017-09-27: Celsion Offers Update On ThermoDox In Phase III OPTIMA Study Of Primary Liver Cancer: 'OPTIMA Study Enrollment is Approaching 70%'

Financial news for CLSN dated on 2017-08-15: Celsion Reports Q2 EPS \$(0.79) vs \$(0.74) Est., Licensing Sales \$125K vs \$60K Est.

Financial news for CLSN dated on 2017-08-15: Earnings Scheduled For August 15, 2017

Financial news for CLSN dated on 2017-08-14: Earnings Scheduled For August 14, 2017

Financial news for CLSN dated on 2017-08-07: Celsion's Data Monitoring Committee Recommends Continuation of Phase III ThermoDox Study

Financial news for CLSN dated on 2017-08-02: Celsion Offers Latest Translational Data From OVATION Study In Newly-Diagnosed Advanced Ovarian Cancer Patients: Patients in All Cohorts Show Convincing Evidence of IL-12 Gene Transfer and Immune System Activity

Financial news for CLSN dated on 2017-07-06: 15 Biggest Mid-Day Losers For Thursday

Financial news for CLSN dated on 2017-07-06: Mid-Day Market Update: Crude Oil Up Over 2%; Egalet Shares Plummet

Financial news for CLSN dated on 2017-07-06: Mid-Morning Market Update: Markets Open Lower; Liberty Interactive To Acquire HSN

Financial news for CLSN dated on 2017-07-06: Celsion Corporation Reports \$5M Registered Direct Offering, Co. Agrees To Sell ~2.435M Shares Of Stock At Price Of \$2.07/Share

Financial news for CLSN dated on 2017-07-06: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for CLSN dated on 2017-07-05: Mid-Afternoon Market Update: Crude Oil Down 3.8%; Monogram Residential Trust Shares Spike Higher

Financial news for CLSN dated on 2017-07-05: 12 Biggest Mid-Day Gainers For Wednesday

Financial news for CLSN dated on 2017-07-05: Mid-Day Market Update: NASDAQ Turns Positive; O'Reilly Shares Drop Following Disappointing Comparable Store Sales

Financial news for CLSN dated on 2017-07-05: Mid-Morning Market Update: Markets Drop; Vantiv To Acquire Worldpay

Financial news for CLSN dated on 2017-07-05: Celsion Shares Up 31.5% On Co. Update Following Completion Of OVATION Study: Highlighted 86% Objective Response Rate In Phase IB Dose Escalating Study, 100% ORR Surgical Resection Rate

Financial news for CLSN dated on 2017-07-05: Celsion Gives Update Following Completion of OVATION Study

Financial news for CLSN dated on 2017-06-29: 13G/A Filing Shows Intracoastal Capital Reporting 1.9% Stake In Celsion

Financial news for CLSN dated on 2017-06-23: 12 Biggest Mid-Day Losers For Friday

Financial news for CLSN dated on 2017-06-22: Celsion Corporation Reports Cancellation of Registered Direct Offering

Financial news for CLSN dated on 2017-06-19: Mid-Afternoon Market Update: Crude Oil Down Over 1%; Clovis Oncology Shares Spike Higher

Financial news for CLSN dated on 2017-06-19: 10 Biggest Mid-Day Losers For Monday

Financial news for CLSN dated on 2017-06-19: Mid-Day Market Update: Dow Gains 100 Points; Performant Financial Shares Tumble

Financial news for CLSN dated on 2017-06-19: Mid-Morning Market Update: Markets Open Higher; EQT To Buy Rice Energy For \$6.7B

Financial news for CLSN dated on 2017-06-19: Celsion Corp. To Sell ~2M Shares Of Stock or Pre-Funded Warrants At Price Of \$2.75/Share

Financial news for CLSN dated on 2017-06-19: Stocks To Watch For June 19, 2017

Financial news for CLSN dated on 2017-06-16: Mid-Afternoon Market Update: Kroger Falls Following Amazon-Whole Foods Deal; Hornbeck Offshore Shares Spike Higher

Financial news for CLSN dated on 2017-06-16: 12 Biggest Mid-Day Gainers For Friday

Financial news for CLSN dated on 2017-06-16: Mid-Day Market Update: Celsion Jumps After Withdrawing Stock Offering; Booz Allen Shares Drop

Financial news for CLSN dated on 2017-06-16: Mid-Morning Market Update: Markets Open Lower; Amazon To Buy Whole Foods For \$13.7 Billion

Financial news for CLSN dated on 2017-06-16: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for CLSN dated on 2017-06-16: A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Housing Starts, Consumer Sentiment Data

Financial news for CLSN dated on 2017-06-16: Celsion +123% Premarket @\$4.35 After Withdrawing Stock Offering

Financial news for CLSN dated on 2017-06-15: Celsion Spikes Higher After Hours to \$2.55

Financial news for CLSN dated on 2017-06-14: Celsion Issues Release Highlighting Regain Compliance With NASDAQ Listing Requirements

Financial news for CLSN dated on 2017-06-06: 11 Biggest Mid-Day Losers For Tuesday

Financial news for CLSN dated on 2017-06-06: Celsion S-1/A Shows Offering Of 3.4M Shares

Financial news for CLSN dated on 2017-06-06: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CLSN dated on 2017-05-26: Celsion Reports Effecting of 1-for-14 Reverse Stock Split

Financial news for CLSN dated on 2017-05-12: Celsion Says Plans to Activate 5 Additional Clinical Trial Sites in Vietnam by Q2 of 2017 for Optima Study

Financial news for CLSN dated on 2017-05-12: Celsion Corporation Reports Q1 EPS \$(0.12) vs \$(0.13) Est., Sales \$125K vs \$90k Est.

Financial news for CLSN dated on 2017-05-12: Earnings Scheduled For May 12, 2017

Financial news for CLSN dated on 2017-05-04: Celsion Provides Updates Clinical Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients

Financial news for CLSN dated on 2017-04-13: Celsion Reports Preclinical Results of ThermoDox for Treatment of Bladder Cancer: Higher Concentrations of Doxorubicin Accumulation and Distribution within the Bladder Wall Were Achieved

Financial news for CLSN dated on 2017-04-10: Benzinga's Top Upgrades, Downgrades For April 10, 2017

Financial news for CLSN dated on 2017-04-10: Rodman & Renshaw Initiates Celsion With Buy, Price Target Of \$1.50/Share

Financial news for CLSN dated on 2017-04-05: S-1 from Celsion Shows Registration for ~6.142M Share Common Stock Offering via Selling Holders

Financial news for CLSN dated on 2017-03-16: Celsion Corporation FY16 EPS \$(0.85) vs. \$(0.85) Est., Sales \$500k vs. \$500k Est.

Financial news for CLSN dated on 2017-02-15: Celsion Reports \$5M Public Offering

Financial news for CLSN dated on 2017-01-17: UPDATE: Celsion Says Fourth Cohort of Patients Continues to Show Clinically Meaningful Responses in the Evaluation of GEN-1 in Combo with Standard of Care

Financial news for CLSN dated on 2017-01-17: Celsion Reports Data from OVATION Study in Newly-Diagnosed Advanced Ovarian Cancer Patients

Financial news for CLSN dated on 2016-12-20: Celsion Reports \$1.8M Registered Direct Offering

Financial news for CLSN dated on 2016-12-16: Celsion Corporation Announces Progress with ThermoDox, CFDA Indicates that Positive Phase III OPTIMA Data Could Support Direct Regulatory Filing in China

Financial news for CLSN dated on 2016-12-01: Celsion Says Will Continue Phase 1b OVATION Study As Planned Following Dosing of Final Patient

Financial news for CLSN dated on 2016-11-30: Celsion Announces Data Monitoring Committee Unanimously Recommends Continuation of Phase III OPTIMA Study of ThermoDox for Primary Liver Cancer

Financial news for CLSN dated on 2016-11-10: UPDATE: Celsion Says 'Top Line Translational Data from First Two Cohorts Demonstrates Potential Immune Activation'

Financial news for CLSN dated on 2016-11-10: Celsion Reports Continuing Positive Data from the OVATION Study: Third Cohort of Patients Continues to Show Clinically Meaningful Responses in the Evaluation of GEN-1

Financial news for CLSN dated on 2016-11-10: Celsion Reports Q3 EPS \$(0.23) vs \$(0.20) Est., Licensing Sales \$125K vs \$130K Est.

Financial news for CLSN dated on 2016-11-04: Celsion Reports Issuance of Two New US Patents for GEN-1 Immuno-Oncology Product

Financial news for CLSN dated on 2016-10-31: Celsion Files For 8.8M Offering By Selling Shareholders

Financial news for CLSN dated on 2016-10-31: Celsion Says 'Supportive Data for the Phase III OPTIMA Study Demonstrates the Potential for a 2 Year Overall Survival Benefit'

Financial news for CLSN dated on 2016-09-15: Celsion Reports DSMB Review of Phase 1b OVATION Study in Ovarian Cancer

Financial news for CLSN dated on 2016-09-12: Celsion Reports Nidenpendent NIH Analysis Showed Treatment with ThermoDox Plus RFA Could Significantly Improve Overall Survival of Patients with Primary Liver Cancer

Financial news for CLSN dated on 2016-08-15: 15 Biggest Mid-Day Gainers For Monday

Financial news for CLSN dated on 2016-08-15: Celsion Reports Q2 EPS \$(0.19) vs \$(0.21) Est., Sales \$125K vs \$80K Est.

Financial news for CLSN dated on 2016-08-15: 12 Stocks Moving In Monday's Pre-Market Session

Financial news for CLSN dated on 2016-08-15: Celsion +21% Premarket @\$1.45 Following Positive ThermoDox Results

Financial news for CLSN dated on 2016-08-15: Celsion Reports Overall Survival Treatment With ThermoDox and Optimized RFA Provided 54% Risk Improvement With P-Value Of 0.02 (Statistically Significant); Chinese Cohort Of Patients Show Clinically Meaningful Benefit

Financial news for CLSN dated on 2016-08-15: Earnings Scheduled For August 15, 2016

Financial news for CLSN dated on 2016-08-09: Celsion Corporation, Zhejiang Hisun Pharmaceutical Company Sign Technology Transfer, Manufacturing and Commercial Supply Agreement for the Development of its GEN-1 Immuno-Oncology Therapy

Financial news for CLSN dated on 2016-07-25: Celsion Announces Positive Data from the OVATION Study

Financial news for CLSN dated on 2016-07-11: Celsion Reports Data from Phase III OPTIMA Study, Experts Endorse Pivotal Study

Financial news for CLSN dated on 2016-06-13: Celsion To Resume Trading At 2:30pm ET

Financial news for CLSN dated on 2016-06-13: Celsion Corporation Reports \$6 Million Registered Direct Offering Of 4.4M Shares At \$1.36/Share

Financial news for CLSN dated on 2016-06-13: Celsion Corp. Halted News Pending

Financial news for CLSN dated on 2016-05-16: Celsion Reports Q1 EPS \$(0.24) vs \$(0.21) Est.

Financial news for CLSN dated on 2016-05-16: Earnings Scheduled For May 16, 2016

Financial news for CLSN dated on 2016-05-02: Celsion Reports Data from First Cohort of Patients in OVATION Study

Financial news for CLSN dated on 2016-04-26: Celsion Corporation Reports Enrollment of Initial Patient in the OPTIMA Study in China

Financial news for CLSN dated on 2016-04-19: Celsion Preclinical GEN-1 IL-12 Studies Show 98% Reduction In Tumor Burden vs. Control

Financial news for CLSN dated on 2016-03-30: Celsion Reports FY15 EPS \$(1.03) vs. Prior Year Quarter \$(1.38), Rev. \$500k vs. Prior Year \$500K

Financial news for CLSN dated on 2016-03-30: Earnings Scheduled For March 30, 2016

Financial news for CLSN dated on 2016-03-16: Celsion Reports Presentation of Preclinical Data for GEN-1 IL-12 in Combo with Avastin, Doxil at AACR Meeting

Financial news for CLSN dated on 2016-03-01: Celsion Reports Issuance of Key US Patent Covering Novel TheraSilence RNA Program

Financial news for CLSN dated on 2016-02-12: UPDATE: Celsion Reported Year-End Cash Position \$20.1M, Down from \$24.1M at the End of Q3

Financial news for CLSN dated on 2016-02-12: Celsion Offers Highlights from Recent Pipeline Developments for GEN-1 Immunotherapy Program

Financial news for CLSN dated on 2015-12-16: Celsion Receives CFDA Approval To Begin

Phase III Optima Study In China

Financial news for CLSN dated on 2015-12-14: Clesion Reports Presentation of DIGNITY Phase 1, 2 ThermoDox Data at San Antonio BCS: Local Responses Observed in 60+% of Evaluable Recurrent Chest Wall Breast Cancer Patients

Financial news for CLSN dated on 2015-11-17: Option Alert: \$CLSN Jan \$4 Call; 936 Contracts @Ask @\$0.10; Ref \$1.84

Financial news for CLSN dated on 2015-11-05: Celsion Corp. Reports Q3 EPS \$(0.19) vs. Est. \$(0.26)

Financial news for CLSN dated on 2015-11-02: Celsion Presents Data on ThermoDox plus Optimized RFA in Intermediate HCC at the 2nd Asian Conference on Tumor Ablation

Financial news for CLSN dated on 2015-10-12: Mid-Afternoon Market Update: Crude Oil Down 5%; SunCoke Energy Shares Dip Following Q3 Results

Financial news for CLSN dated on 2015-10-12: Morning Market Gainers

Financial news for CLSN dated on 2015-10-12: Celsion Reports Preclinical Data for GEN-1 IL-12 Immunotherapy in Combo with Avastin, Doxil for Ovarian Cancer: Data Shows Significant Synergistic Anti-Cancer Effects

Financial news for CLSN dated on 2015-09-30: Celsion Corporation Enrolls First Patient in the OVATION Study

Financial news for CLSN dated on 2015-08-10: Celsion Reports Q2 Loss of \$0.27/Share vs Loss of \$0.31/Share Est., Licensing Sales \$125K vs Loss of \$110K Est.

Financial news for CLSN dated on 2015-08-06: Celsion Corporation Reports Updated Overall Survival Data from HEAT Study of ThermoDox(r) in Primary Liver Cancer

Financial news for CLSN dated on 2015-07-15: Morning Market Gainers

Financial news for CLSN dated on 2015-07-15: Benzinga's Top Initiations

Financial news for CLSN dated on 2015-07-15: Maxim Group Initiates Coverage on Celsion at Buy, Announces \$12.00 PT

Financial news for CLSN dated on 2015-07-13: Celsion Shares Rise 12% After-Hours; Nearing Initiation at BTIG With Buy, \$10 PT

Financial news for CLSN dated on 2015-07-13: BTIG Research Initiates Coverage on Celsion at Buy, Announces \$10.00 PT

Financial news for CLSN dated on 2015-07-06: Morning Market Gainers

Financial news for CLSN dated on 2015-07-06: Benzinga's Top #PreMarket Gainers

Financial news for CLSN dated on 2015-07-06: Celsion Reports Ongoing Positive Data from Its Phase 2 DIGNITY Study in Breast Cancer

Financial news for CLSN dated on 2015-06-05: 13G Filing from Frigate Ventures on Celsion Shows New 6.5% Stake

Financial news for CLSN dated on 2015-06-01: Celsion Presents GEN-1 Immunotherapy Phase 1b Results For Recurrent Ovarian Cancer at ASCO 2015, Observed Clinical Benefit With Highest Dosage

Financial news for CLSN dated on 2015-05-28: Morning Market Losers

Financial news for CLSN dated on 2015-05-28: Celsion Reports \$8M At-The-Market Direct Registered Offering

Financial news for CLSN dated on 2015-05-21: Celsion Announces Potent, Durable Preclinical Lung Expression Data for Its Novel TheraSilence RNA Program

Financial news for CLSN dated on 2015-05-13: Celsion Corporation Announces ASCO 2015 GEN-1 Immunotherapy Phase 1b Results in Ovarian Cancer Presentation

Financial news for CLSN dated on 2015-05-12: Celsion Reports Q1 Rev. Inline vs. \$125K

Financial news for CLSN dated on 2015-05-12: Celsion Corp. Reports Q1 EPS \$(0.35) vs. Est. \$(0.33)

Financial news for CLSN dated on 2015-05-11: Earnings Scheduled For May 11, 2015

Financial news for CLSN dated on 2015-04-29: Celsion Expands Clinical Development

Plan for GEN-1 IL-12 Immunotherapy Program in Ovarian Cancer

Financial news for CLSN dated on 2015-04-15: Morning Market Gainers

Financial news for CLSN dated on 2015-04-15: Clesion Reports Positive Interim Data from Phase 2 DIGNITY Trial: Will Initiate Euro-DIGNITY Trial This Quarter

Financial news for CLSN dated on 2015-03-12: Celsion Corp. Reports FY14 EPS \$(1.38) vs. Est. \$(1.42), Rev. \$500k vs. Est. \$120K

Financial news for CLSN dated on 2015-02-23: Celsion Says Results at 2 Years Post Treatment Continue to Support Protocol For Ongoing Phase III Optima Trial

Financial news for CLSN dated on 2015-02-23: Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox(r) in Primary Liver Cancer

Financial news for CLSN dated on 2015-02-20: UPDATE: Celsion Slightly Falls Back Following Treatment News

Financial news for CLSN dated on 2015-02-20: Celsion Jumps On Interim Data On Cancer Drug

Financial news for CLSN dated on 2015-02-20: Morning Market Gainers

Financial news for CLSN dated on 2015-02-20: Celsion Shares Spike Higher at Open; May be Attributed to Seeking Alpha Post

Financial news for CLSN dated on 2015-02-20: Celsion Corporation Presents Data for GEN-1 IL-12 Immunotherapy At Molecular Medicine TRI-Conference

Financial news for CLSN dated on 2015-01-20: Celsion Corporation, myTomorrows Partner To Introduce ThermoDox

Financial news for CLSN dated on 2015-01-06: Celsion Reports Submission of DNA-Based Immunotherapy Clinical Protocol to FDA Related to Part of First-Line Treatment for Ovarian Cancer

Financial news for CLSN dated on 2014-11-05: Celsion Corporation Receives VHP Approval to Initiate OPTIMA Study in Europe

Financial news for CLSN dated on 2014-10-30: Benzinga's Top Initiations

Financial news for CLSN dated on 2014-10-30: Canaccord Genuity Initiates Celsion With Buy

Financial news for CLSN dated on 2014-10-30: Canaccord Genuity Initiates Coverage on Celsion Corporation at Buy, Announces \$7.00 PT

Financial news for CLSN dated on 2014-10-29: Celsion Presents Preclinical Data for its TheraSilence(tm) Platform at the miRNA World Conference Workshop on miRNA Delivery

Financial news for CLSN dated on 2014-10-29: Celsion Presents Preclinical Data For Its TheraSilence Platform At The miRNA World Conference Workshop On miRNA Delivery

Financial news for CLSN dated on 2014-09-16: S-3 Filing from Celsion Shows Registration for 3.38M Share Shelf Offering Through EGWU Inc.

Financial news for CLSN dated on 2014-09-04: Celsion Reports Consolidated Duke University and Celsion's DIGNITY Study Clinical Data on ThermoDox(r) in Recurrent Chest Wall Breast Cancer Published in the International Journal of Hyperthermia

Financial news for CLSN dated on 2014-09-02: Celsion Announces Enrollment Of First Patient In Global Phase 3 OPTIMA Study Of ThermoDox

Financial news for CLSN dated on 2014-08-15: Celsion Director Martinez Buys 5,000 Shares @\$3.12/Share -Form 4

Financial news for CLSN dated on 2014-08-07: Celsion Corporation Reports Q2 EPS of \$(0.38) vs \$(0.32) Est; Revenue of \$125.0M vs \$130.0K Est

Financial news for CLSN dated on 2014-07-28: Celsion Announces Positive Results From HEAT Study

Financial news for CLSN dated on 2014-07-24: Morning Market Movers

Financial news for CLSN dated on 2014-07-24: Celsion Reports Positive Interim Data from Phase 2 DIGNITY Breast Cancer Study

Financial news for CLSN dated on 2014-06-11: Celsion Corporation CEO Tardugno Buys 5,000 Shares @\$3.20/Share -Form 4

Financial news for CLSN dated on 2014-06-11: Celsion Corporation Director Martinez Jr Buys 5,000 Shares @\$3.20/Share -Form 4

Financial news for CLSN dated on 2014-06-10: Benzinga's M&A Chatter for Tuesday June 10, 2014

Financial news for CLSN dated on 2014-06-10: Shares of Celsion Resume Trade, Now Up 20.5%

Financial news for CLSN dated on 2014-06-10: PREVIEW: Celsion to Resume Trading at 8:00 AM ET

Financial news for CLSN dated on 2014-06-10: Celsion to Acquire EGEN For \$14M, Up to An Additional \$30.4M In Milestone Payments

Financial news for CLSN dated on 2014-06-10: Celsion Announces Will Purchase EGEN for \$14M in Cash, Shares

Financial news for CLSN dated on 2014-06-10: Celsion Halted News Pending

Financial news for CLSN dated on 2014-05-21: Celsion Gets Clearance To Start Phase 3 OPTIMA Study

Financial news for CLSN dated on 2014-05-08: Celsion Corporation Reports Q1 EPS of \$(0.33) vs \$(0.24) Est; Revenue of \$125.0K vs \$130.0K Est

Financial news for CLSN dated on 2014-04-24: Celsion to Present Updated Overall Survival Results from HEAT Study of ThermoDox at ECIO 2014

Financial news for CLSN dated on 2014-04-24: Celsion Announces Updated Overall Survival Results from the HEAT Study of ThermoDox in Primary Liver Cancer Presented at ECIO 2014

Financial news for CLSN dated on 2014-04-10: Celsion Says Recent Analysis Indicates ThermoDox Could Significantly Improve Overall Survival

Financial news for CLSN dated on 2014-03-13: Celsion Corporation Reports FY EPS of \$(0.95); Revenue of \$500.0K

Financial news for CLSN dated on 2014-02-28: Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving Higher, ELGX, DECK, MDVN, CGEN, ARNA Low

Financial news for CLSN dated on 2014-02-27: Celsion Reports Positive Interim Data from Phase 2 DIGNITY Trial in Breast Cancer

Financial news for CLSN dated on 2014-02-13: Celsion Spikes Higher; May be Attributed to Seeking Alpha Post

Financial news for CLSN dated on 2014-01-27: Celsion Announces Results Support Continued Clinical Development of ThermoDox in a Prospective Pivotal Phase III Study

Financial news for CLSN dated on 2014-01-15: Celsion Announces \$15M At-The-Market Registered Direct Offering

Financial news for CLSN dated on 2014-01-15: Celsion Announces \$15M ATM Direct Offering, Sees Net Proceeds ~\$13.8M

Financial news for CLSN dated on 2013-12-13: Morning Market Movers

Financial news for CLSN dated on 2013-12-13: Celsion Presents Combined Clinical Data from Two Phase I Trials

Financial news for CLSN dated on 2013-11-12: Celsion Corporation Reports Q3 EPS of \$(0.30), Up 63% YOY

Financial news for CLSN dated on 2013-10-28: Celsion Reports 1-for-4.5 Reverse Stock Split

Financial news for CLSN dated on 2013-09-30: HC Wainwright Initiates Coverage on Celsion Corporation at Buy, Announces \$2.25 PT

Financial news for CLSN dated on 2013-09-09: Stocks to Watch for September 9, 2013

Financial news for CLSN dated on 2013-07-19: Celsion Corporation and Zhejiang Hisun Pharmaceutical Company Sign Memorandum of Understanding for Future Development of ThermoDox(r) and Other Liposomal Formulations

Financial news for CLSN dated on 2013-07-02: Celsion Announces Jeffrey W. Church Reappointed to CFO

Financial news for CLSN dated on 2013-06-20: Morning Market Movers

Financial news for CLSN dated on 2013-06-20: Celsion Shares Rally as Co. Announces Review of ThermoDox HEAT Study

Financial news for CLSN dated on 2013-06-20: Celsion Rises 22% Pre-Market on Phase 3 ThermoDox(r) HEAT Study Presentation

Financial news for CLSN dated on 2013-06-17: Afternoon Market Losers

Financial news for CLSN dated on 2013-06-14: Afternoon Market Losers

Financial news for CLSN dated on 2013-06-12: Celsion Corporation Issues Statement Regarding Misleading Blog Entry

Financial news for CLSN dated on 2013-06-12: Afternoon Market Losers

Financial news for CLSN dated on 2013-06-12: Morning Market Losers

Financial news for CLSN dated on 2013-06-03: Celsion Shares Higher; May be Attributed to Seeking Alpha Article

Financial news for CLSN dated on 2013-05-31: Celsion Falling; Trading Lower on \$9.83M Direct Offering

Financial news for CLSN dated on 2013-05-31: Celsion Prices 6.26M Shares at \$1.57/Share

Financial news for CLSN dated on 2013-05-31: Celsion Spikes Lower

Financial news for CLSN dated on 2013-05-30: Shares of Celsion Continuing Sharply Higher as Co. Shows Study Data on ThermoDox Showing Meaningful PFS, Survival Benefits; Stock Now Up 75% Over Last Six Sessions

Financial news for CLSN dated on 2013-05-29: Afternoon Market Gainers

Financial news for CLSN dated on 2013-05-17: Celsion Shares Moving Higher as Traders Cheer Findings from ThermoDox HEAT Study

Financial news for CLSN dated on 2013-04-23: Celsion Shares Rally as Co. Hires Cantor Fitzgerald to Evaluate Purchase Alternatives, Study Shows ThermoDox Improves PFS with Optimized Heating

Financial news for CLSN dated on 2013-04-18: Stocks Hitting 52-Week Lows

Financial news for CLSN dated on 2013-03-18: Celsion Corporation Reports FY EPS of \$(0.76) vs \$(0.72) Est

Financial news for CLSN dated on 2013-03-18: Earnings Scheduled For March 18, 2013

Financial news for CLSN dated on 2013-02-11: Morning Market Movers

Financial news for CLSN dated on 2013-02-05: Celsion Announces Zhejiang HISUN Pharmaceutical does Not Plan to Pursue Exclusive Option to License ThermoDox for China

Financial news for CLSN dated on 2013-02-04: Stocks Hitting 52-Week Lows

Financial news for CLSN dated on 2013-02-01: Stocks Hitting 52-Week Lows

Financial news for CLSN dated on 2013-01-31: Roth Capital Downgrades Celsion Corporation to Neutral, Lowers PT to \$1.70

Financial news for CLSN dated on 2013-01-31: Celsion Resumes Trading -81%

Financial news for CLSN dated on 2013-01-31: Celsion Resumes Trading

Financial news for CLSN dated on 2013-01-31: PREVIEW: Celsion Corporation to Resume Trading at 7:30 AM ET

Financial news for CLSN dated on 2013-01-30: Celsion Halted Wednesday, Says Will Host Conference Call Jan 31

Financial news for CLSN dated on 2013-01-30: Celsion Says Heat Study Receives Fast Track Designation from FDA

Financial news for CLSN dated on 2013-01-30: Celsion Halted News Pending

Financial news for CLSN dated on 2013-01-17: Brean Capital Downgrades Celsion Corporation to Sell, Lowers PT to \$1.00

Financial news for CLSN dated on 2013-01-16: Celsion Resumes Trading

Financial news for CLSN dated on 2013-01-16: Celsion Gap Down May be Attributed to Seeking Alpha Article

Financial news for CLSN dated on 2013-01-16: Celsion Halted on Circuit Breaker

Financial news for CLSN dated on 2013-01-14: Celsion Spikes Higher

Financial news for CLSN dated on 2012-12-12: Stocks Hitting 52-Week Highs

Financial news for CLSN dated on 2012-12-11: Celsion Shares Push Over \$8 Following Disclosure of Director Buy of 14K Shares on Dec. 10th

Financial news for CLSN dated on 2012-11-27: UPDATE: Dawson James Initiates Celsion at Market Outperform on Phase III Catalyst

Financial news for CLSN dated on 2012-11-27: Dawson James Initiates Coverage Celsion at Market Outperform, Announces PT of \$9

Financial news for CLSN dated on 2012-11-12: Celsion Reports Q3 EPS \$-0.18 vs \$-0.17 Est

Financial news for CLSN dated on 2012-10-01: Celsion Corp Says Continuing Phase 2 Study

Financial news for CLSN dated on 2012-09-14: Celsion Thermodox Gets Orphan Drug Status in US/Europe

Financial news for CLSN dated on 2012-08-14: Celsion Reports Q2 EPS \$-0.18 vs \$-0.19 Est

Financial news for CLSN dated on 2012-08-13: Celsion Files \$75M Mixed Securities Shelf

Financial news for CLSN dated on 2012-08-08: Option Alert: Celsion October 2.5 Put; Block Trade: 3,805 Contracts @\$0.20; Currently \$3.13

Financial news for CLSN dated on 2012-06-28: Celsion Corporation Announces \$10 Million Loan Facility

Financial news for CLSN dated on 2012-06-25: Option Alert: Celsion Call Volume at 2,303% of Average; Currently 3.01

Financial news for CLSN dated on 2012-06-25: Option Alert: Celsion July 4 Call; Block Trade: 13,404 Contracts; Currently \$2.95

Financial news for CLSN dated on 2012-06-19: Celsion CEO Says More Than One Multinational Pharmaceutical Company Has Shown Interest in Licensing Thermodox -Reuters

Financial news for CLSN dated on 2012-06-19: Celsion CEO Says Chance Thermodox Could Be Approved By End of 2013 -Reuters

Financial news for CLSN dated on 2012-06-07: Option Alert: Celsion Put Volume at 1,067% of Average; Currently \$2.25

Financial news for CLSN dated on 2012-06-07: Celsion Announces Collaboration With the University of Oxford for First Ever Clinical Trial Using a Targeted Chemotherapeutic Drug Released by Ultrasound to Treat Cancer

Financial news for CLSN dated on 2012-05-30: Option Alert: Celsion Put Volume at 932% of Average; Currently \$1.94

Financial news for CLSN dated on 2012-05-30: Celsion Announces Completion of Enrollment in Its Pivotal Phase III HEAT Study of ThermoDox(R) in Primary Liver Cancer

Financial news for CLSN dated on 2012-05-14: UPDATE: Celsion, Philips Expect To Initiate Clinical Study Following FDA Acceptance

Financial news for CLSN dated on 2012-05-14: Celsion Announces Resubmission With Philips Healthcare of Combined IND/IDE Application for a Phase 2 Study of

ThermoDox(R) and MR-Guided HIFU in Bone Cancer

Financial news for CLSN dated on 2012-05-07: Celsion Announces ThermoDox Commercial Supply Agreement With Hisun

Financial news for CLSN dated on 2012-04-26: Option Alert: Celsion Put Volume at 948% of Average (\$2.06)

Financial news for CLSN dated on 2012-04-23: Celsion Announces Data Monitoring Committee Unanimously Recommends Continuation of Phase III HEAT Study of ThermoDox

Financial news for CLSN dated on 2012-02-16: Brean Murray Carret & Co. Initiates Coverage on Celsionoration at Buy, Announces PT of \$7

Financial news for CLSN dated on 2012-02-13: Celsion Announces First Patient Enrolled in Phase II Study of ThermoDox(R) in Combination With RFA in Colorectal Liver Metastases

Financial news for CLSN dated on 2012-01-23: Option Alert: Celsion July 1.5 Call; Block Trade, 2,950 Contracts

Financial news for CLSN dated on 2011-12-28: Notable Put Options Activity on Celsion

Financial news for CLSN dated on 2011-12-20: Rodman & Renshaw Maintains Outperform on Celsion

Financial news for CLSN dated on 2011-12-19: Celsion Completes Consultative Review Process With EMA for Phase III HEAT Study of ThermoDox in Primary Liver Cancer

Financial news for CLSN dated on 2011-12-01: Notable Call Options Activity in Celsion

Financial news for CLSN dated on 2011-12-01: Celsion Corporation to Raise \$15 Million in Private Placement

Financial news for CLSN dated on 2011-11-28: Celsion Announces Unanimous Recommendation by Independent Data Monitoring Committee to Continue and Complete Phase III HEAT Study of ThermoDox in Primary Liver Cancer as Planned

Financial news for CLSN dated on 2011-11-14: Rodman & Renshaw Reiterates Outperform, \$6 PT on Celsion Corp

Financial news for CLSN dated on 2011-11-04: Celsion Spiking Higher on Heavy Volume

Financial news for CLSN dated on 2011-11-01: Celsion's Technical Breakout Appears to Have Upcoming News Wings

Financial news for CLSN dated on 2011-10-26: Rodman & Renshaw Initiates Coverage on Celsion With an Outperform Rating

Financial news for CLSN dated on 2011-10-26: Rodman & Renshaw Initiates Celsion Corporation at Market Outperform, \$6 PT

Financial news for CLSN dated on 2011-10-12: Notable Call Options Activity in Celsion

Financial news for CLSN dated on 2011-09-28: Notable Put Options Activity in Celsion

Financial news for CLSN dated on 2011-09-12: Celsion Presenting Now at Rodman and Renshaw Healthcare Conference

Financial news for CLSN dated on 2011-09-06: Notable Call Options Activity in Celsion

Financial news for CLSN dated on 2011-08-29: Celsion Scream Higher; Breaks Through Resistance

Financial news for CLSN dated on 2011-08-18: Celsion Announces Approval of \$1.2M New Jersey Economic Development Authority Incentive Grant

Financial news for CLSN dated on 2011-08-17: Celsion Announces Publication of Clinical and Scientific Review of ThermoDox as Treatment for Primary Liver Cancer

Financial news for CLSN dated on 2011-08-04: Celsion Corp Violently Falling on Heavy Volume

Financial news for CLSN dated on 2011-08-03: Celsion Reaches Major Milestone With Enrollment of 600th Patient in Its Pivotal Phase III HEAT Study of ThermoDox in Primary Liver Cancer

Financial news for CLSN dated on 2011-07-21: Celsion Corporation Announces \$18.4 Million in Financing

Financial news for CLSN dated on 2011-07-20: Unconfirmed Rumors Circulate that Phase III Results of Stimuvax Endpoint Results May Have Been Leaked

Financial news for CLSN dated on 2011-07-20: Oncothyreon Gaps Higher Pre-Market Following Celsion, Cancer Sector Rally

Financial news for CLSN dated on 2011-07-20: Stocks to Watch for Wednesday 7/20/2011: Fresh 52 Week Highs and Lows

Financial news for CLSN dated on 2011-07-14: Stocks to Watch for Thursday 7/14/2011: Fresh 52 Week Highs and Lows

Financial news for CLSN dated on 2011-07-12: Celsion Appoints Gregory Weaver as CFO

Financial news for CLSN dated on 2011-07-07: Celsion Racing Toward Daily Highs

Financial news for CLSN dated on 2011-07-01: Options Brief: Celsion Corporation

Financial news for CLSN dated on 2011-07-01: Celsion Corporation Announces \$6.6 Million Registered Direct Offering

Financial news for CLSN dated on 2011-06-10: Options Brief: Celsion Corporation

Financial news for CLSN dated on 2011-06-01: Options Brief: Celsion Corporation

Financial news for CLSN dated on 2011-05-27: Options Brief: Celsion Corporation

Financial news for CLSN dated on 2011-05-27: Celsion Corporation Announces \$8.6M Equity Offering of Common Stock and Warrants

Financial news for CLSN dated on 2011-05-13: Top Percentage Gainers and Losers as of 12pm 5/13/11 (ABIO, DDS, GFRE, APL, VRML, DF, SWSH, CLSN, AERL, CA, NVDA, QTWW, IMRS, FFHL, MPG, GENE)

Financial news for CLSN dated on 2011-05-11: Celsion Corporation Regains Compliance With NASDAQ Listing Requirements (CLSN)

Financial news for CLSN dated on 2011-04-26: Options Brief: Celsion Corporation (CLSN)

Financial news for CLSN dated on 2011-03-18: Celsion Corporation to Host Year-End 2010 Earnings Call and Webcast on Friday, March 25, 2011

Financial news for CLSN dated on 2011-01-21: Celsion Corporation Announces Completion of \$5.1 Million Registered Direct Offering

Financial news for CLSN dated on 2011-01-13: Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to \$9 Million

Financial news for CLSN dated on 2010-11-15: Celsion Reports Third Quarter EPS of \$(0.38)

Financial news for CLSN dated on 2010-11-02: Celsion Awarded Therapeutic Discovery Project Grant From US Government

Financial news for CLSN dated on 2010-10-04: Celsion Receives Positive FDA Guidance for its New Drug Application

Financial news for CLSN dated on 2010-09-30: Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox(r) HEAT Study

Financial news for CLSN dated on 2010-09-02: Celsion Receives SBIR Grant (CLSN)

Financial news for CLSN dated on 2010-07-13: 7-13-10 The Small Cap Market Update from Express IR

Financial news for CLSN dated on 2010-04-16: Stocks That Have Crossed 52-Week Highs (ARBA, CACH, CKEC, CLSN, DISCB)

Financial news for CLSN dated on 2010-02-11: Benzinga's Pre-market Gainers (ARGN, NTGR, OPEN, LIOX, CLSN)

Financial news for CLSN dated on 2009-09-28: Biggest Losers (XRX, FRP, CLSN, CRXL, QTWW)